Key Takeaways
- CMS Administrator nominee Mehmet Oz pledged to maintain and defend the Medicare price negotiation program, but also said during his Senate confirmation hearing he will explore other ideas to lower drug costs, if confirmed.
- International reference pricing is one of many potential approaches he could pursue.
- Oz also suggested the CMMI demonstration project on sickle cell gene therapy could help facilitate access to the treatment and an annuity approach to payment could be successful.
US Centers for Medicare and Medicaid Services Administrator nominee Mehmet Oz is committed to defending the Medicare price negotiation program, but will also pursue other ways to lower drug costs...
“It’s the law. I’m going to defend it and use it,” he said in response to a question from Sen. Ben Ray Lujan, D-NM, during his 14 March confirmation hearing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
